title: Perioperative plasma neutrophil gelatinase-associated lipocalin measurement in patients who undergo left ventricular assist device implantation surgery.
abstract: BACKGROUND
  Perioperative complication of end-organ injury including acute kidney injury (AKI) is a frequent and severe problem for patients undergoing left ventricular assist device (LVAD) implantation. This study evaluated an emerging AKI biomarker, plasma neutrophil gelatinase-associated lipocalin (NGAL), in a LVAD implantation cohort.
  
  
  RESULTS
  Of 31 LVAD implantation patients enrolled to this study, 17 (55%) patients were diagnosed as having AKI. Six AKI patients showed severe AKI requiring renal replacement therapy (RRT). Plasma NGAL values in the AKI-with-RRT group (n=6) were significantly higher than that in other patients, although the AKI-without-RRT (n=11) group showed a similar level of plasma NGAL to that of the non-AKI group (n=14). Multiple logistic regression analysis revealed that plasma NGAL measured at pre-operation and central venous pressure at pre-operation and 12 h after surgery independently discriminated against postoperative RRT requirement. In the AKI-with-RRT group, plasma NGAL decreased before termination of RRT in 4 patients who eventually showed renal recovery, although no decline of plasma NGAL was observed in 2 patients who showed no recovery of renal function. Removal of blood NGAL by continuous hemodiafiltration was shown to be 70-75% lower than that of creatinine.
  
  
  CONCLUSIONS
  Measurement of perioperative plasma NGAL is useful for predicting severe AKI requiring RRT and renal recovery in patients who have had LVAD implantation surgery. Further investigation is necessary to confirm these findings because this study examined a low number of patients.
authors.affiliation: Department of Nephrology and Endocrinology, The University of Tokyo.
authors.forename: Maki
authors.initials: M
authors.lastname: Sumida
authors.forename: Kent
authors.initials: K
authors.lastname: Doi
authors.forename: Osamu
authors.initials: O
authors.lastname: Kinoshita
authors.forename: Mitsutoshi
authors.initials: M
authors.lastname: Kimura
authors.forename: Minoru
authors.initials: M
authors.lastname: Ono
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Hamasaki
authors.forename: Takehiro
authors.initials: T
authors.lastname: Matsubara
authors.forename: Takeshi
authors.initials: T
authors.lastname: Ishii
authors.forename: Naoki
authors.initials: N
authors.lastname: Yahagi
authors.forename: Masaomi
authors.initials: M
authors.lastname: Nangaku
authors.forename: Eisei
authors.initials: E
authors.lastname: Noiri
mesh_terms: D058186:Acute Kidney Injury / Q000097:blood* / Q000209:etiology / Q000628:therapy; D000209:Acute-Phase Proteins; D000328:Adult; D005260:Female; D006353:Heart-Assist Devices; D006801:Humans; D000071068:Lipocalin-2; D054834:Lipocalins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D019990:Perioperative Care; D059035:Perioperative Period; D011183:Postoperative Complications / Q000097:blood* / Q000628:therapy; D019919:Prosthesis Implantation / Q000009:adverse effects*; D011518:Proto-Oncogene Proteins / Q000097:blood*; D017582:Renal Replacement Therapy
chemical_list: D000209:Acute-Phase Proteins; C489506:LCN2 protein, human; D000071068:Lipocalin-2; D054834:Lipocalins; D011518:Proto-Oncogene Proteins